In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii , P. aeruginosa and Enterobacterales
Journal of Antimicrobial Chemotherapy · 01.12.2023 · 78 (12) · 2801-2809
DOI: 10.1093/jac/dkad244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 16.10.2023. Verfasst von Aliaa Fouad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Acinetobacter baumannii. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Entasis Therapeutics.
Abstract (Originalsprache)
Background
Sulbactam-durlobactam is a potent combination active against Acinetobacter baumannii; however, it lacks activity against other nosocomial pathogens. Cefepime is a common first-line therapy for hospital/ventilator-associated pneumonia caused by Gram-negative pathogens including Pseudomonas aeruginosa and Enterobacterales. With increasing resistance to cefepime, and the significant proportion of polymicrobial nosocomial infections, effective therapy for infections caused by Acinetobacter baumannii, P. aeruginosa and Enterobacterales is needed. This study investigated the in vitro synergy of sulbactam-durlobactam plus cefepime against relevant pathogens.
Methods
Static time–kills assays were performed in duplicate against 14 cefepime-resistant isolates (A. baumannii, n = 4; P. aeruginosa, n = 4; Escherichia coli, n = 3; Klebsiella pneumoniae, n = 3). One WT K. pneumoniae isolate was included. Antibiotic concentrations simulated the free-steady state average concentration of clinically administered doses in patients.
Results
Sulbactam-durlobactam alone showed significant activity against A. baumannii consistent with the MIC values. Sulbactam-durlobactam plus cefepime showed synergy against one A. baumannii isolate with an elevated MIC to sulbactam-durlobactam (32 mg/L). Against all P. aeruginosa isolates, synergy was observed with sulbactam-durlobactam plus cefepime. For the Enterobacterales, one E. coli isolate demonstrated synergy while the others were indifferent due to significant kill from sulbactam-durlobactam alone. The combination of sulbactam-durlobactam plus cefepime showed synergy against one of the K. pneumoniae and additive effects against the other two K. pneumoniae tested. No antagonism was observed in any isolates including the WT strain.
Conclusions
Synergy and no antagonism was observed with a combination of sulbactam-durlobactam and cefepime; further in vivo pharmacokinetic/pharmacodynamics data and clinical correlation are necessary to support our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
- Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
ORCID-Profile: Christian M Gill
Förderung
- Entasis Therapeutics
Zitieren
APA
Fouad, A., Nicolau, D. P., & Gill, C. M. (2023). In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii , P. aeruginosa and Enterobacterales. Journal of Antimicrobial Chemotherapy, 78(12), 2801-2809. https://doi.org/10.1093/jac/dkad244
Vancouver
Fouad A, Nicolau DP, Gill CM. In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii , P. aeruginosa and Enterobacterales. Journal of Antimicrobial Chemotherapy. 2023;78(12):2801-2809. doi:10.1093/jac/dkad244
BibTeX
@article{Fouad2023,
author = {Fouad, Aliaa and Nicolau, David P and Gill, Christian M},
title = {In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii , P. aeruginosa and Enterobacterales},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {12},
pages = {2801--2809},
doi = {10.1093/jac/dkad244}
}
EUVIMED